All In Biotech

Drug Trial Radar · NCT05874869

Dihydroartemisinin-piperaquine for Seasonal Malaria Chemoprophylaxis in Tanzania

Effectiveness of Dihydroartemisinin-piperaquine as Seasonal Malaria Chemoprophylaxis in Extended High Transmission Settings of Tanzania: an Open Cluster Randomized Clinical Trial.

Last checked: Nov 20, 2026Latest source record: May 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 13,800 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

13,800

Actual

Start

Jul 1, 2020

Primary completion

Jun 30, 2021

Study completion Jun 30, 2021

Sponsor

Lead sponsor
Richard MwaisweloGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Muhimbili University of Health and Allied Sciences; National Institute for Medical Research, Tanzania; Hubert Kairuki Memorial University
First posted
May 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 3 months, up to 59 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background: Malaria prevalence has declined globally following the scale-up of the interventions, including insecticide-treated bed-net, indoor residual spraying, and prompt diagnosis and treatment with artemisinin-based combination therapy (ACT). Despite the gained success in the control, malaria has remained a major public health problem, particularly affecting children aged \< 5 years in sub-Saharan Africa. Most of the malaria transmissions occur during the rainy season, a relatively short period. Intervention using antimalarial chemotherapy in children during the transmission season has been shown to prevent malaria-related morbidity and mortality. The World Health Organization has recommended seasonal malaria chemoprevention (SMC) using Sulphadoxine-pyrimethamine (SP) plus amodiaquine (AQ) in children aged 3-59 months in areas with highly seasonal malaria transmission. However, SP-AQ resistance is widespread in Tanzania. Therefore, this study will assess the effectiveness of Dihydroartemisinin-piperaquine (DHA-PQ) as SMC for the control of malaria among children in Tanzania. Methods: Afebrile children aged 3-59 months from Nanyumbu and Masasi districts in the Mtwara region will be enrolled in an open cluster randomized clinical trial, administered monthly with a full course of DHA-PQ for three or four consecutive months during the high malaria transmission season of the three consecutive years. Three approaches of DHA-PQ SMC administration will be tested; a door-to-door approach using community health workers (CHWs), outreach visits using local health facilities clinicians/nurses, and village health posts using selected CHWs. Study participants will then be followed-up to evaluate the impact of the intervention on all-course of malaria morbidity and mortality; adverse events associated with the intervention; acceptability, adherence, coverage, and cost-effectiveness of the intervention; treatment-seeking behavior; and the risk of rebound after the withdrawal of the intervention. The primary outcome will be a prevalence of clinical malaria defined as the presence of fever (axillary temperature of 37.5 degrees Celsius) or a history of fever in the past 24 hours and the presence of P. falciparum asexual parasitemia at any density. Findings: The findings will be disseminated through community meetings, seminars, local and international conferences, and publication in international journals. Impact: The findings from this study will provide information on the effectiveness of DHA-PQ for seasonal prevention of malaria morbidity and mortality in children aged \< 5 years in Tanzania.

Conditions

  • Malaria
  • Chemoprophylaxis
  • Underfive Children

Interventions

  • Dihydroartemisinin-piperaquineDrug

    The drug will be administered once a day for three consecutive days for three months (March, April, and May)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Prevalence of clinical malariaTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Muhimbili University of Health and Allied Ssciences

    Dar es Salaam, Tanzania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.